acetic acid;N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | 202256-98-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: acetic acid;N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
• CAS: 202256-98-2
• 化学式: C19H22F3NO3
• 分子量: 369.4
• InChiKey: QACACUUSDJIARA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.53
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Novel formulations for the transdermal administration of fluoxetine
  申请人：ALZA CORPORATION

  公开号：EP1393724A2

  公开（公告）日：2004-03-03

  A device for the transdermal administration of fluoxetine (10) at a therapeutically effective rate comprises: (a) a reservoir (12) containing a composition comprising an amount of a pharmaceutically acceptable salt of fluoxetine; (b) a backing (14) behind the body contacting-distal surface of the reservoir; and (c) means (16) for maintaining the reservoir in fluoxetine transmitting relation with a body surface or membrane.

  一种以治疗有效率透皮给药氟西汀（10）的装置包括 (a) 储液器 (12)，其中含有一定量的氟西汀药学上可接受的盐； (b) 在储液器与身体接触的远端表面后面的衬垫（14）；以及 (c) 使储液器与身体表面或膜保持氟西汀传递关系的装置（16）。
• Novel formulations for the administration of fluoxetine
  申请人：——

  公开号：US20030166624A1

  公开（公告）日：2003-09-04

  Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.

  用于体表或体膜的物质组合物，通过体表或体膜渗透给药氟西汀，该组合物包含以治疗有效率单独或与渗透促进剂或混合物结合给药的氟西汀。一个优选的实施方案是关于降低皮肤刺激水平的氟西汀透皮给药，其中氟西汀（最好以醋酸氟西汀的形式提供）与皮质类固醇（如氢化可的松）联合给药。还公开了含有氟西汀或氟西汀和增强剂组合物的给药装置，以及氟西汀和氟西汀/增强剂组合物的透皮给药方法。
• NOVEL FORMULATIONS FOR THE ADMINISTRATION OF FLUOXETINE
  申请人：ALZA CORPORATION

  公开号：EP0946184A2

  公开（公告）日：1999-10-06
• NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FLUOXETINE ACETATE AND FLUOXETINE MALEATE
  申请人：ALZA Corporation

  公开号：EP0946184B1

  公开（公告）日：2004-09-29
• US6203817B1
  申请人：——

  公开号：US6203817B1

  公开（公告）日：2001-03-20